Related Experiment Videos
Cost effectiveness in the treatment of hypertension
1Department of Preventive Medicine, University of Tennessee, Veterans Affairs Medical Center, Memphis 38104.
Clinics in Geriatric Medicine
|November 1, 1989
Insights
Treating high blood pressure in older adults lowers heart risks. The choice of medication significantly impacts the cost-effectiveness of preventing cardiovascular death, with variations up to tenfold.
Area of Science:
- Gerontology
- Cardiology
- Health Economics
Background:
- Elderly patients with hypertension are at increased risk of cardiovascular mortality.
- Effective treatment strategies are crucial for improving outcomes in this population.
- The economic implications of different treatment regimens warrant investigation.
Purpose of the Study:
- To evaluate the impact of drug regimen selection on the cost per prevented cardiovascular death in hypertensive elderly patients.
- To determine the range of cost-effectiveness across different antihypertensive drug choices.
Main Methods:
- Comparative analysis of drug regimens for hypertension in elderly patients.
- Calculation of cost per cardiovascular death prevented for each regimen.
- Assessment of cost-effectiveness based on available clinical data.
Main Results:
- Significant variations exist in the cost per cardiovascular death prevented among different drug regimens.
- Certain drug regimens demonstrate a tenfold greater cost-effectiveness than others.
- Regimen choice is a critical factor in the economic efficiency of hypertension management.
Conclusions:
- Optimizing drug selection in hypertensive elderly patients can lead to substantial cost savings in preventing cardiovascular mortality.
- Healthcare providers and policymakers should consider cost-effectiveness when choosing antihypertensive treatments for the elderly.
- Further research into cost-effective hypertension management strategies is recommended.
Abstract:
Treatment of hypertensive elderly patients reduces cardiovascular mortality. The drug regimen selected affects the cost per prevented death. Drug regimens may have a tenfold difference in cost per cardiovascular death prevented.